| Ytd | 183.77% | |
| 1y | 57.38% |
| Open | 3.56 | Prev Close | 3.58 | Low | 3.56 | High | 3.59 | Mkt Cap | 16.73M |
| Vol | 1.75K | Avg Vol | 29.52K | EPS | -1.15 | P/E | -3.11 | Forward P/E | -2.44 |
| Beta | 1.76 | Short Ratio | 0.78 | Inst. Own | 40.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.40 | 200-d Avg | 2.34 | 1yr Est | 4.00 |
CYCN News
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti
NEW YORK, April 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.
MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for pos
Under the deal, the combined company is expected to operate as Korsana Biosciences and trade on the
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN)
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phas
AEVA: 40% | Aeva Technologies' Frequency Modulated Continuous Wave 4D LiDAR Technology Selected
BeyondSpring (NASDAQ: BYSI - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Re
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaborati
Response Genetics (OTCMKTS:RGDXQ - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get F
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, Pr
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that w
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), tod
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), tod
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experi
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Th
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash P